Iovance Biotherapeutics (IOVA) Receivables - Net (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Receivables - Net for 4 consecutive years, with $81.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 15.25% year-over-year to $81.8 million; the TTM figure through Mar 2026 stood at $81.8 million (up 15.25% YoY), while the FY2025 annual figure was $82.4 million, up 18.9% from the prior year.
• Receivables - Net fell to $81.8 million in Q1 2026 per IOVA's latest filing, from $82.4 million in the prior quarter.
• Across five years, Receivables - Net topped out at $82.4 million in Q4 2025 and bottomed at $33000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $47.2 million across 4 years, with a median of $59.9 million in 2025.
• Annual changes were most pronounced in 2024 — Receivables - Net jumped 95669.7% — and 2026, when it climbed 15.25%.
• Iovance Biotherapeutics' Receivables - Net stood at $151000.0 in 2023, then jumped by 45820.53% to $69.3 million in 2024, then grew by 18.9% to $82.4 million in 2025, then slipped by 0.84% to $81.8 million in 2026.
• Business Quant data shows IOVA's Receivables - Net at $81.8 million in Q1 2026, $82.4 million in Q4 2025, and $66.8 million in Q3 2025.